Hospira (NYSE:HSP) must deal with an FDA citation regarding a plant in India, even the federal safety watchdog lifted a warning on its infusion pump plant in Costa Rica.
Lake Forest, Ill.-based Hospira said in a recent regulatory filing that the FDA cited its pharmaceutical facility in Visakhapatnam, India, after an inspection last month. Hospira said it will respond to all of the as-yet-unnamed issues the FDA outlined in what is known as a Form 483, which regulators issue when they see potential violations.
Help employers find you! Check out all the jobs and post your resume.
